Evaxion biotech announces q2 2021 financial results and provides business update

Copenhagen, denmark, aug. 12, 2021 (globe newswire) -- evaxion biotech a/s (nasdaq: evax) (“evaxion” or the “company”), a clinical-stage biotechnology company specializing in the development of ai-driven immunotherapies to improve the lives of patients with cancer, bacterial diseases and viral infections, announced today the second quarter 2021 financial results and provided an operational update.
EVAX Ratings Summary
EVAX Quant Ranking